Aisling Capital

company

About

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by

  • 11 - 50

Details

Industries
Biotechnology,Health Care,Venture Capital
Founded date
Jan 1, 2000
Number Of Employee
11 - 50
Operating Status
Active
Investor Type
PE

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.

Investments

Number of Investments
Number of Lead Investments
12
1
Aisling Capital has made 12 investments. Their most recent investment was on Sep 12, 2022, when Forge Biologics raised $90M.
Date Company Name
Round Money Raised Industry Lead Investor
Sep 12, 2022 Forge Biologics
Series C $90M Biotechnology Yes
Nov 13, 2017 Arcus Biosciences
Series C $107M Biotechnology
Jun 8, 2016 Miramar Labs
Series Unknown Health Care
Jul 24, 2015 ViewRay
Post-IPO Equity $26.70M Biotechnology
Oct 6, 2014 Miramar Labs
Series D $26M Health Care